Galectin Therapeutics Inc (GALT) 3.84 $GALT
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 6.80 (+0.03), RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
NeoStem Announces Addition of Experienced Scientist and Biotechnology Executive Peter G. Traber, MD, to Its Board of Directors
GlobeNewswire - Thu Jan 22, 7:30AM CST
NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, today announced the addition of Peter G. Traber, MD, to its Board of Directors.
NBS: 3.78 (+0.14), GALT: 3.84 (+0.16), GSK: 47.94 (+1.99)
Regado Bio and Tobira to merge
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 8:42AM CST
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02)
Securities Lending Notable Names: JCP, AMBA
Interactive Brokers - at Seeking Alpha - Tue Jan 13, 2:32AM CST
Strong sales guidance gave some life to struggling department store operator, J.C. Penney Co., Inc. (NYSE: JCP ) last week following a prolonged period of negative news. The stock soared approximately 17% on Tuesday of last week after the company...
AMBA: 50.71 (-4.46), GPRO: 45.27 (-0.02), EDAP: 3.55 (+0.13), LNCO: 12.30 (+0.28), IMRS: 1.04 (-0.03), GALT: 3.84 (+0.16), JCP: 8.05 (+0.14), MOC: 2.24 (+0.02), BIND: 6.06 (+0.21), LINE: 12.94 (+0.40), JOB: 0.79 (+0.01), BCLI: 3.86 (-0.02), NDRM: 10.76 (+0.22)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OFED: 20.41 (+0.16), SIBC: 21.10 (+0.22), NBIX: 37.22 (+0.27), ANTH: 3.84 (+0.06), GALT: 3.84 (+0.16), BRID: 7.55 (-0.04), BIOD: 1.38 (-0.14), ARNA: 4.55 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 11:45AM CST
KOPN: 3.91 (-0.10), ZFGN: 39.06 (+0.92), CYNI: 3.93 (+0.14), NEON: 2.98 (+0.16), BALT: 1.74 (+0.09), GALT: 3.84 (+0.16), ESNT: 24.18 (+0.16), CHOP: 0.87 (-0.01), LIQT: 1.16 (+0.01), ENPH: 15.15 (+0.37), KBIO: 0.45 (+0.06), NERV: 4.68 (+0.09), REN: 1.14 (unch), FWM: 5.55 (+0.08), COSI: 2.80 (unch), JCP: 8.05 (+0.14), PKT: 8.99 (+0.11), ARNA: 4.55 (+0.02), BGI: 1.41 (-0.05), MERU: 2.74 (-0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:20AM CST
FRO: 2.96 (+0.07), GGB: 3.59 (+0.09), KBIO: 0.45 (+0.06), SONC: 31.59 (-0.37), JCP: 8.05 (+0.14), GALT: 3.84 (+0.16), SNE: 27.30 (+0.19), RMTI: 11.17 (+0.15), PKT: 8.99 (+0.11), ARNA: 4.55 (+0.02)
Galectin up on Phase 1 results in NASH
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 7:50AM CST
GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for Therapeutic Effect on Fibrosis in NASH Patients With Advanced Fibrosis
GlobeNewswire - Wed Jan 07, 7:00AM CST
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that final results from its Phase 1 trial show that GR-MD-02 had an effect on a serum biomarker (as assessed by FibroTest(R)) and liver stiffness (as assessed by FibroScan) that suggest a potential for therapeutic effect on fibrosis that warrants further exploration. This first-in-man study, which enrolled 30 patients in three cohorts, principally evaluated the safety, tolerability and pharmacokinetics for single and multiple doses of its galectin-inhibiting drug GR-MD-02 when administered intravenously to patients with fatty liver disease, or nonalcoholic steatohepatitis (NASH) with advanced fibrosis. The study also secondarily examined exploratory biomarkers as well as a newer non-invasive liver stiffness measure. Final Phase 1 data are included in a new corporate presentation which is available on the Company's website (www.galectintherapeutics.com).
GALT: 3.84 (+0.16)
Turnaround potential? 2014's worst performers in the Russell 2000
Seeking Alpha - at Seeking Alpha - Sun Jan 04, 2:49PM CST
KWK: 0.15 (unch), BPZ: 0.25 (unch), EXXI: 4.00 (+0.42), MBII: 3.88 (+0.33), MILL: 2.07 (+0.09), PHMD: 1.68 (+0.04), PRKR: 1.07 (+0.04), RLOC: 3.58 (+0.42), NTLS: 5.19 (+0.05), VTG: 0.52 (-0.02), GDP: 3.58 (+0.29), REN: 1.14 (unch), CYTX: 0.47 (unch), XONE: 16.93 (-0.16), KEG: 2.14 (+0.08), REXX: 5.08 (+0.13), AMZG: 0.65 (-0.03), COVS: 2.47 (+0.11), EXEL: 2.48 (+0.20), ANV: 0.97 (-0.03), VRNG: 0.81 (+0.01), FUEL: 14.30 (+0.65), ZQK: 2.26 (+0.05), GALT: 3.84 (+0.16), EOX: 1.15 (unch), SALT: 2.17 (+0.18), MM: 1.67 (+0.07), WLT: 1.09 (+0.05), NADL: 2.10 (-0.02), QRHC: 1.30 (+0.03), MCP: 0.97 (+0.04), ANR: 1.27 (+0.03), ARO: 3.63 (+0.04), RGDO: 1.17 (+0.02), HERO: 0.92 (+0.02), FWM: 5.55 (+0.08), CONN: 24.69 (-0.07), MPO: 1.00 (-0.02), CVEO: 3.87 (+0.15), SZYM: 2.64 (+0.02)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 43.76 (+0.61), RPTP: 9.05 (-0.40), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), TBRA: ()
The 2015 Calendar Of NASH Trial Catalysts II: Galectin Therapeutics And La Jolla Pharmaceutical Co.
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 6:37AM CST
LJPC: 18.79 (unch), GALT: 3.84 (+0.16)
Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference
GlobeNewswire - Mon Dec 01, 11:30AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James C. Czirr, executive chairman of the Company's board of directors, will present at the LD Micro "Main Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014 at 11:30 a.m. PST at the Luxe Sunset Bel Air Hotel in Los Angeles, Calif.
GALT: 3.84 (+0.16)
Galectin NASH treatment meets primary endpoint in Phase 1
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:12AM CST
GALT: 3.84 (+0.16)
Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program
GlobeNewswire - Mon Nov 10, 7:43AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the third quarter and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission. The Company also provided an update on its development program.
GALT: 3.84 (+0.16)
Galectin Therapeutics beats by $0.10
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:25AM CST
GALT: 3.84 (+0.16)
Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development
GlobeNewswire - Sun Nov 09, 2:30PM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, presented data today from the Company's Phase 1 clinical trial of GR-MD-02 in NASH (fatty liver disease) patients with advanced fibrosis at The Liver Meeting in Boston, Massachusetts. Stephen A. Harrison, MD, Chief of Hepatology at Brooke Army Medical Center in Fort Sam Houston and a clinical trial investigator in Galectin Therapeutics' Phase 1 clinical trial, shared the data during an oral presentation at the 65 Annual Meeting of the American Association for the Study of Liver Diseases.
GALT: 3.84 (+0.16)
Galectin Therapeutics' Abstract Accepted as Oral Presentation at The Liver Meeting(R), Annual Meeting of the American Association for the Study of Liver Diseases
GlobeNewswire - Wed Oct 01, 12:45PM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company's abstract titled "Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis" was accepted as an oral presentation at The Liver Meeting, the 65th Annual Meeting of the American Association for the Study of Liver Diseases. The presentation will be made on Sunday, November 9, 2014 at 3:30pm Eastern Standard Time at the Hynes Convention Center in Boston, Mass.
GALT: 3.84 (+0.16)
EQUITY ALERT: Rosen Law Firm Reminds Galectin Therapeutics, Inc. Investors of Important September 29, 2014 Class Action Deadline -- GALT
GlobeNewswire - Fri Sep 26, 5:37PM CDT
The Rosen Law Firm, P.A. reminds purchasers of Galectin Therapeutics, Inc. (Nasdaq:GALT) securities between January 6, 2014 and July 28, 2014, of the important September 29, 2014 lead plaintiff deadline in the class action.
GALT: 3.84 (+0.16)
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 6.80 (+0.03), RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
NeoStem Announces Addition of Experienced Scientist and Biotechnology Executive Peter G. Traber, MD, to Its Board of Directors
GlobeNewswire - Thu Jan 22, 7:30AM CST
NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, today announced the addition of Peter G. Traber, MD, to its Board of Directors.
NBS: 3.78 (+0.14), GALT: 3.84 (+0.16), GSK: 47.94 (+1.99)
Regado Bio and Tobira to merge
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 8:42AM CST
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02)
Securities Lending Notable Names: JCP, AMBA
Interactive Brokers - at Seeking Alpha - Tue Jan 13, 2:32AM CST
Strong sales guidance gave some life to struggling department store operator, J.C. Penney Co., Inc. (NYSE: JCP ) last week following a prolonged period of negative news. The stock soared approximately 17% on Tuesday of last week after the company...
AMBA: 50.71 (-4.46), GPRO: 45.27 (-0.02), EDAP: 3.55 (+0.13), LNCO: 12.30 (+0.28), IMRS: 1.04 (-0.03), GALT: 3.84 (+0.16), JCP: 8.05 (+0.14), MOC: 2.24 (+0.02), BIND: 6.06 (+0.21), LINE: 12.94 (+0.40), JOB: 0.79 (+0.01), BCLI: 3.86 (-0.02), NDRM: 10.76 (+0.22)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OFED: 20.41 (+0.16), SIBC: 21.10 (+0.22), NBIX: 37.22 (+0.27), ANTH: 3.84 (+0.06), GALT: 3.84 (+0.16), BRID: 7.55 (-0.04), BIOD: 1.38 (-0.14), ARNA: 4.55 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 11:45AM CST
KOPN: 3.91 (-0.10), ZFGN: 39.06 (+0.92), CYNI: 3.93 (+0.14), NEON: 2.98 (+0.16), BALT: 1.74 (+0.09), GALT: 3.84 (+0.16), ESNT: 24.18 (+0.16), CHOP: 0.87 (-0.01), LIQT: 1.16 (+0.01), ENPH: 15.15 (+0.37), KBIO: 0.45 (+0.06), NERV: 4.68 (+0.09), REN: 1.14 (unch), FWM: 5.55 (+0.08), COSI: 2.80 (unch), JCP: 8.05 (+0.14), PKT: 8.99 (+0.11), ARNA: 4.55 (+0.02), BGI: 1.41 (-0.05), MERU: 2.74 (-0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:20AM CST
FRO: 2.96 (+0.07), GGB: 3.59 (+0.09), KBIO: 0.45 (+0.06), SONC: 31.59 (-0.37), JCP: 8.05 (+0.14), GALT: 3.84 (+0.16), SNE: 27.30 (+0.19), RMTI: 11.17 (+0.15), PKT: 8.99 (+0.11), ARNA: 4.55 (+0.02)
Galectin up on Phase 1 results in NASH
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 7:50AM CST
GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for Therapeutic Effect on Fibrosis in NASH Patients With Advanced Fibrosis
GlobeNewswire - Wed Jan 07, 7:00AM CST
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that final results from its Phase 1 trial show that GR-MD-02 had an effect on a serum biomarker (as assessed by FibroTest(R)) and liver stiffness (as assessed by FibroScan) that suggest a potential for therapeutic effect on fibrosis that warrants further exploration. This first-in-man study, which enrolled 30 patients in three cohorts, principally evaluated the safety, tolerability and pharmacokinetics for single and multiple doses of its galectin-inhibiting drug GR-MD-02 when administered intravenously to patients with fatty liver disease, or nonalcoholic steatohepatitis (NASH) with advanced fibrosis. The study also secondarily examined exploratory biomarkers as well as a newer non-invasive liver stiffness measure. Final Phase 1 data are included in a new corporate presentation which is available on the Company's website (www.galectintherapeutics.com).
GALT: 3.84 (+0.16)
Turnaround potential? 2014's worst performers in the Russell 2000
Seeking Alpha - at Seeking Alpha - Sun Jan 04, 2:49PM CST
KWK: 0.15 (unch), BPZ: 0.25 (unch), EXXI: 4.00 (+0.42), MBII: 3.88 (+0.33), MILL: 2.07 (+0.09), PHMD: 1.68 (+0.04), PRKR: 1.07 (+0.04), RLOC: 3.58 (+0.42), NTLS: 5.19 (+0.05), VTG: 0.52 (-0.02), GDP: 3.58 (+0.29), REN: 1.14 (unch), CYTX: 0.47 (unch), XONE: 16.93 (-0.16), KEG: 2.14 (+0.08), REXX: 5.08 (+0.13), AMZG: 0.65 (-0.03), COVS: 2.47 (+0.11), EXEL: 2.48 (+0.20), ANV: 0.97 (-0.03), VRNG: 0.81 (+0.01), FUEL: 14.30 (+0.65), ZQK: 2.26 (+0.05), GALT: 3.84 (+0.16), EOX: 1.15 (unch), SALT: 2.17 (+0.18), MM: 1.67 (+0.07), WLT: 1.09 (+0.05), NADL: 2.10 (-0.02), QRHC: 1.30 (+0.03), MCP: 0.97 (+0.04), ANR: 1.27 (+0.03), ARO: 3.63 (+0.04), RGDO: 1.17 (+0.02), HERO: 0.92 (+0.02), FWM: 5.55 (+0.08), CONN: 24.69 (-0.07), MPO: 1.00 (-0.02), CVEO: 3.87 (+0.15), SZYM: 2.64 (+0.02)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 43.76 (+0.61), RPTP: 9.05 (-0.40), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), TBRA: ()
The 2015 Calendar Of NASH Trial Catalysts II: Galectin Therapeutics And La Jolla Pharmaceutical Co.
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 6:37AM CST
LJPC: 18.79 (unch), GALT: 3.84 (+0.16)
Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference
GlobeNewswire - Mon Dec 01, 11:30AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James C. Czirr, executive chairman of the Company's board of directors, will present at the LD Micro "Main Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014 at 11:30 a.m. PST at the Luxe Sunset Bel Air Hotel in Los Angeles, Calif.
GALT: 3.84 (+0.16)
Galectin NASH treatment meets primary endpoint in Phase 1
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:12AM CST
GALT: 3.84 (+0.16)
Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program
GlobeNewswire - Mon Nov 10, 7:43AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the third quarter and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission. The Company also provided an update on its development program.
GALT: 3.84 (+0.16)
Galectin Therapeutics beats by $0.10
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:25AM CST
GALT: 3.84 (+0.16)
Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development
GlobeNewswire - Sun Nov 09, 2:30PM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, presented data today from the Company's Phase 1 clinical trial of GR-MD-02 in NASH (fatty liver disease) patients with advanced fibrosis at The Liver Meeting in Boston, Massachusetts. Stephen A. Harrison, MD, Chief of Hepatology at Brooke Army Medical Center in Fort Sam Houston and a clinical trial investigator in Galectin Therapeutics' Phase 1 clinical trial, shared the data during an oral presentation at the 65 Annual Meeting of the American Association for the Study of Liver Diseases.
GALT: 3.84 (+0.16)
Galectin Therapeutics' Abstract Accepted as Oral Presentation at The Liver Meeting(R), Annual Meeting of the American Association for the Study of Liver Diseases
GlobeNewswire - Wed Oct 01, 12:45PM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company's abstract titled "Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis" was accepted as an oral presentation at The Liver Meeting, the 65th Annual Meeting of the American Association for the Study of Liver Diseases. The presentation will be made on Sunday, November 9, 2014 at 3:30pm Eastern Standard Time at the Hynes Convention Center in Boston, Mass.
GALT: 3.84 (+0.16)
EQUITY ALERT: Rosen Law Firm Reminds Galectin Therapeutics, Inc. Investors of Important September 29, 2014 Class Action Deadline -- GALT
GlobeNewswire - Fri Sep 26, 5:37PM CDT
The Rosen Law Firm, P.A. reminds purchasers of Galectin Therapeutics, Inc. (Nasdaq:GALT) securities between January 6, 2014 and July 28, 2014, of the important September 29, 2014 lead plaintiff deadline in the class action.
GALT: 3.84 (+0.16)
